This pathology tutorial provides a detailed approach to the diagnosis of atypical fibroxanthoma (AFX) and its distinction from other high-grade, pleomorphic spindle cell neoplasms of the skin, including undifferentiated pleomorphic sarcoma (UPS, or pleomorphic dermal sarcoma/PDS). These lesions typically present on the sun-exposed head and neck of elderly patients, often clinically mimicking squamous cell carcinoma. Histologically, they show marked pleomorphism, hyperchromatic nuclei, and atypical mitoses, making differentiation from spindle cell melanoma and spindle cell squamous cell carcinoma (SCC) mandatory. The diagnosis relies heavily on a targeted immunohistochemistry (IHC) panel, specifically using Sox10/S100 to exclude melanoma and P63/P40 to exclude SCC. Once these mimics and other rare sarcomas (e.g., leiomyosarcoma, angiosarcoma) are ruled out, the distinction between AFX and UPS/PDS hinges on the depth of invasion: AFX is confined strictly to the dermis and has a low risk of metastasis, whereas UPS/PDS extends into the subcutis and is considered a true sarcoma with metastatic potential. Due to frequent broad transection of initial biopsies, surgical re-excision is usually required to definitively assess the deep margin and establish the precise diagnosis and prognosis.
Summary of Atypical Fibroxanthoma (AFX) and Undifferentiated Pleomorphic Sarcoma (UPS/PDS)
0:05 Naming and Definition: The video focuses on differentiating Atypical Fibroxanthoma (AFX) from Undifferentiated Pleomorphic Sarcoma (UPS), formerly Malignant Fibrous Histiocytoma (MFH), which is now often called Pleomorphic Dermal Sarcoma (PDS) when confined to the skin and subcutaneous tissue.
0:43 Typical Presentation: These lesions occur primarily on the head and neck of elderly, sun-exposed patients. Clinically, they often present as ulcerated, scaly nodules that are impossible to differentiate from squamous cell carcinoma (SCC) without a biopsy.
1:37 Histology (Low Power): The dermis is filled with atypical, pleomorphic, and enormous spindle cells arranged haphazardly or in short fascicles. There is usually no associated in situ malignancy in the overlying epidermis.
2:28 Core Differential Diagnosis: When faced with ugly, atypical spindle cells in a skin biopsy, the top three diagnoses are Spindle Cell Melanoma, Spindle Cell SCC, and AFX. These three entities can look histologically identical on H&E.
3:26 Signs of Malignancy (Pleomorphism): A key feature is pleomorphism, defined as the largest tumor nucleus being at least three times the size of the smallest. Other features include huge, hyperchromatic nuclei, central nucleoli, and atypical mitotic figures (e.g., tripolar/Y-shaped/asymmetric).
6:00 Mandatory IHC Panel: Immunohistochemistry is essential because H&E is insufficient for diagnosis, especially since poorly differentiated SCC and melanoma can lack in-situ components or typical morphology.
6:50 Excluding Melanoma: Use Sox10 (and/or S100). Sox10 is a sensitive nuclear stain for melanocytes and is preferred over S100 because it avoids staining background Langerhans/dendritic cells, which can cause confusion in inflamed/ulcerated biopsies.
9:48 Excluding SCC: Use P63 or P40 (nuclear markers) as the primary screen. Pan-cytokeratin is unreliable because poorly differentiated SCC often loses CK expression. P63 is rarely positive in mesenchymal tumors like AFX.
11:34 Other Sarcomas to Exclude: Leiomyosarcoma (use Desmin, avoid relying solely on Actin) and Angiosarcoma (use ERG or CD31, as hemorrhage suggests this possibility).
15:50 Prognostic Distinction (AFX vs. Sarcoma): After excluding other entities, the differentiation between AFX and PDS/UPS is based on depth:
AFX: Confined completely to the dermis; almost never metastasizes despite atypical appearance.
PDS/UPS: Extends into the subcutaneous fat; considered a true sarcoma with metastatic potential (up to 30% in some series).
16:06 Reporting Challenge: Most initial skin biopsies are broadly transected across the deep margin, making it impossible to confirm dermal confinement.
16:28 Takeaway & Recommendation: The tumor should be reported as "Pleomorphic spindle cell neoplasm" with AFX and PDS/UPS in the differential. Re-excision is required to assess the base of the lesion, determine true depth, and guide definitive treatment.
18:44 DFSP Exclusion: Dermatofibrosarcoma Protuberans (DFSP) is typically cytologically bland and non-pleomorphic, effectively excluding it from this high-grade differential.